Fulgent Genetics price target lowered to $65 from $70 at Piper Sandler

Piper Sandler analyst David Westenberg lowered the firm’s price target on Fulgent Genetics to $65 from $70 and keeps an Overweight rating on the shares. The analyst updated his model to reflect the recent earnings report.